Vor Biopharma Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 30.8 million compared to USD 28.43 million a year ago. Basic loss per share from continuing operations was USD 0.45 compared to USD 0.43 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.51 USD | -2.89% | -12.21% | -32.89% |
05-13 | Oppenheimer Adjusts Vor Biopharma Price Target to $10 From $15, Maintains Outperform Rating | MT |
05-09 | Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.89% | 103M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.09% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+27.49% | 12.08B | |
+22.40% | 11.94B |
- Stock Market
- Equities
- VOR Stock
- News Vor Biopharma Inc.
- Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024